RE: BHPHere's my read on Protox:
It is no surprise that efforts are focused on BPH Phase 2 as it is closest to commercialization. I understand that is what was said at the AGM in June. So far nothing has changed on the timetable. PRX expects enrollment in BPH Phase 2 to be complete in Q3 (i.e. by September 09) with results released in Q4.
The 12 month follow up on the open label study is due in Q3 as well; I suspect this may be annouunced at Protox's presentataion at the Rodman Conference in New York City (September 9-11).
I am very positive on PRX as all clinicals to date on BPH have prodcued a superior outcome with ZERO downside risk. It should be a slam dunk; but as we all know, anything can happen in cinical trials. That is part of the "why the stock is low" with the other part being a conservative promotion strategy.
I like how PRX is lining up its ducks. The two most recent BOD appontments speak to that: a NDA submission resource and a licensing resource.
If BPH Phase 2 is positive (as most expect it will be given the consistency of all previous trial results) we should expect a deal shortly thereafter (for BPH or the entire company). I am sure talks are advanced on a "what if" basis. While PRX won't break the code on the double blinded trial, it should be fairly obvious that one cell is outperforming the other...unless there has been a HUGE PLACEBO EFFECT in all the BPH studies to date...and unlikely scenario.
In the meantime, small scale efforts are being directed to other therapeutic areas such as prostate and brain cancer pipeline or sale.
Comments from others would be appreciated.
jb